Journal article
The clinical implications of left ventricular diastolic dysfunction in systemic sclerosis
L Ross, S Patel, W Stevens, A Burns, D Prior, A La Gerche, M Nikpour
Clinical and Experimental Rheumatology | CLINICAL & EXPER RHEUMATOLOGY | Published : 2022
Abstract
Objective We sought to quantify the burden of left ventricular diastolic dysfunction (LVDD) and heart failure with preserved ejection fraction (HFpEF) in systemic sclerosis (SSc) and assess the progression of LVDD over time and its prognostic importance. Methods Two-hundred and twenty-five participants enrolled in the Australian Scleroderma Cohort Study were included and LVDD was assessed according to 2016 ASE/EACVI Guidelines. Logistic regression analyses and generalised estimating equations were performed to evaluate the relationship between LVDD and SSc disease characteristics and symptoms and signs of heart failure, respectively. The relationship between LVDD and mortality was assessed u..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia Investigator Grant
Funding Acknowledgements
the Australian Scleroderma Cohort Study is supported by Actelion Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, The Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, The Australian Rheumatology Association, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies, Bristol-Myers Squibb and private philanthropic donations. L. Ross is supported by an Arthritis Australia - Australian Rheumatology Association (Victoria) Fellowship, A. La Gerche is a National Heart Foundation of Australia Future Leadership Fellowship and M. Nikpour holds a National Health and Medical Research Council of Australia Investigator Grant (GNT 1176538).